ABVC BioPharma announced that Vitargus Phase II Site Initiation Visit at Srinagarind Hospital, Khon Kaen University was successfully conducted on March 9-10. The SIV was an organized meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABVC:
- ABVC BioPharma’s Maitake Mushroom Dietary Supplement approved in Taiwan
- ABVC BioPharma provides 2023 pipeline update
- ABVC BioPharma Provides 2023 Pipeline Update
- ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
- ABVC receives Australian TGA approval to initiate Phase II study of vitargus
